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Abstract
Nuclear factor kB (NFkB) activation plays a crucial role in anti-apoptotic responses in response to the apoptotic signaling
during tumor necrosis factor (TNFa) stimulation in Multiple Myeloma (MM). Although several drugs have been found
effective for the treatment of MM by mainly inhibiting NFkB pathway, there are not any quantitative or qualitative results of
comparison assessment on inhibition effect between different drugs either used alone or in combinations. Computational
modeling is becoming increasingly indispensable for applied biological research mainly because it can provide strong
quantitative predicting power. In this study, a novel computational pathway modeling approach is employed to
comparably assess the inhibition effects of specific drugs used alone or in combinations on the NFkB pathway in MM and to
predict the potential synergistic drug combinations.
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Introduction
Combined drug interventions are a common therapeutic strategy
for complex diseases such as cancer [1]. As pointed out recently for
cancer therapy [2], most therapies were initally developed as
effective single agents and only later combined clinically. It is very
important to previously predict the single drug-effect for effective
drug selection related to specific diseases due to the huge number of
drug agents. Moreover, a possible approach to the exploration of
new theapeutic activities is not only present in individual drugs but
also based on the exhaustive study of all possible combinations of
compounds [3]. However, for drug combination strategy, time-
consuming and expensive screening is needed to find promising
combinatorial candidates from the vast number of natural and
synthetic compounds available, and to see if they produce an
appropriate biochemical or cellular effect [4]. Algorithms of making
this drug combination screening faster, more effective and less
expensive are in a continual development, such as synergistic
combination screening [5], genetic algorithm [6] and floating
forward selection [1]. However, all of these methods did not take
insights into the drug effects on detailed signaling pathways. It is
well-known that drug effects are governed by the intrinsic properties
of the drug and the specific signal transduction network of the host
such as disease cells. Predictability starts to become an important
issue at the very begining of a discovery programme. Selection of a
protein target is often based on evidence that the specific protein is
significant in a pathway relevant to the disease of interest, this
evidence perhaps being in the form of a knock-out showing an effect
in changing cell physiology, and on evidence that the protein
target’s function can be affected by the binding of a drug molecule
to it. This approach is deeply ingrained in the current intellectual
furniture in drug discovery, and is characterised as the basis for
‘rational drug discovery’ [7]. Based on this concept, in this work we
takeTNFa-induced NFkB signalingpathway in MM as an example
to show how to reach the aim of ‘rational drug discovery’ by
combining computational pathway modeling approach with
dynamic experimental data.
MM is the second most common hematologic malignancy, with
about 15,000 new cases per year in USA, and remains incurable
with a median survival of 3 to 5 years [8]. It is a plasma cell
malignancy characterized by complex heterogeneous cytogenetic
abnormalities. The bone marrow microenvironment promotes
MM cell growth and resistance to conventional therapies [9].
Failure of myeloma cells to undergo apoptosis plays an important
role in the accumulation of myeloma cells within the bone
marrow. Several anti-apoptotic proteins and anti-apoptotic
signaling cascades have been identified that contribute to the
anti-apoptotic phenotype of the myeloma cells [8,9,10]. Actually,
adhesion of myeloma cells to bone marrow stromal cells (BMSCs)
triggers none-cytokine and cytokine-mediated tumour cell growth,
survival, drug resistance and migration. MM cells binding to
BMSCs upregulates cytokine secretion from both BMSCs and
tumour cells. These cytokines activate major signaling pathways:
extracellular signal-regulated kinase (ERK); Janus kinase 2
(JAK2)/signal transducer and activator of transcription 3
(STAT3); phosphatidylinositol 3-kinase (PI3K)/AKT; and NFkB.
These pathways not only promote growth, survival and migration
of MM cells, but also confer resistance to conventional
chemotherapy. Targeting these mechanisms or inhibiting these
pathways offers a potential therapeutic strategy to induce the
apoptosis of MM cells and overcome drug resistance.
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e14750It has previously shown that canonical NFkB pathway in MM
cells is mainly activated by TNFa [11,12]. Several drugs effective
for the treatment of MM, including bortezomib (BZM), thalido-
mide, lenalidomide and arsenic trioxide (ATO), have been found
to block NFkB activation [13]. Therefore, blockade of TNFa-
induced NFkB signaling by different single drugs or different drug
combinations represent a novel therapeutic strategy in MM.
However, at least to the best of our knowledge, there are no any
quantitative or qualitative results of comparison assessment on
inhibition effects between these different single drugs or drug
combinations. So, we do not know how to choose drugs to inhibit
the NFkB pathway, or we do not know which drug is the best one?
What is the best dose for specific single drug? What is the best ratio
and dose for specific drug combination? How about the inhibition
effect if the drug combination is chosen with fixed ratio and dose?
To answer these questions, a mass of biological experiments have
to be designed to compare the inhition effects. However this
tradional approach is time-consuming and expensive.
Computaional modeling is becoming increasingly indispensable
for basic and applied biological research. Essentially, a mathe-
matical model is a systematic representation of biological system,
whose analysis can confer quantitative predicting power. One of
the common applications of mathematical modeling is to analyze
cellular networks systematically and another use of mathematical
modeling has been demonstrated in devising strategies to control
cellular dynamics. Therefore, the computational modeling is
suitable for signaling pathway analysis and drug combination
response analysis in our study.
In this paper, we try to employ the computational modeling
approach to assess or predict the specific drug (used alone or in
combination) responses on inhibition of NFkB pathway in MM.
We firstly develop the computational model qualitatively, and then
collect some specific experimental data to estimate the model
parameters, and further design specific simulation protocols to
predict the responses for single drugs and drug combinations. The
workflow is presented in Figure 1. At first, a qualitative system for
NFkB pathway is constructed based on the procedure beginning
from qualitative pathway to graphical model and then to the
ordinary differential equations (ODEs) system description. Then
dynamic experimental data are collected, and optimization
method is employed to estimate the unknown model parameters
based on the dynamic experimental data. So, the quantitative
system is built after the procedure of parameter estimation, and
then parameter sensitivity analysis is used to asses the stability of
the constructed system. After that, the considered drugs are
modeled into the quantitative system based on specific mecha-
nisms of actions and the complete ODEs system with or without
drug treatments is constructed after the modification of ODEs
with input of drugs. Then the simulation protocols are designed to
predict the drug effects based on the quantification methods.
Therefore, predicted drug profiles are presented for specific single
drugs and drug combinations from model simulations, especially
for the prediction of synergy on drug combinations based on Bliss
combination index or Loewe isobologram quantification methods.
Results
Construction of qualitative system for general NFkB
pathway
To understand the interaction mechanisms of various molecular
species in the NFkB activation module, we model this dynamical
system using a set of ODEs, which can be used to systematically
describe the time dynamics of concentrations for all the
components in the pathway. For this purpose, the primary step
is usually to construct the qualitative system. Firstly, the qualitative
NFkB pathway collected from biological literatures is described
(see Figure 2). Based on the qualitative pathway, the graphical
model is then constructed (see Figure 3), and this model give us all
of the details about the considered NFkB pathway including all of
the reactions and all of the molecules related to the pathway and
also all of the symbols of parameters in the ODEs model. In fact,
this model provides us a clear idea on how to build the whole
ODEs system for this model. Further, the detailed computational
model with ODEs system is developed based on this graphical
model (see Materials and Methods).
To facilitate the development of the computational model for
NFkB pathway in MM, the following basic assumptions are made
firstly.
Figure 1. Workflow of the systematic procedure to predict drug-effects. (A) A qualitative system for general NFkB pathway is constructed
based on the procedure from qualitative pathway, graphical model, to ODEs system description. (B) Dynamic experimental data are collected, and
then optimization method is employed to estimate the unknown model parameters based on the dynamic data. (C) The quantitative system for
specific NFkB pathway in MM is built after parameter estimation procedure, and then parameter sensitivity analysis is used to assess the stability of
the constructed system. (D) The considered drugs are modeled into the quantitative system based on specific mechanism of actions. (E) The
complete ODEs system with or without drug treatments is constructed after the ODEs modification for drug input. (F) Simulation protocols are
designed to predict the drug effects based on the quantification methods. (G) Predicted drug profiles are presented for specific single drugs and drug
combinations from model simulation.
doi:10.1371/journal.pone.0014750.g001
Drug Prediction from Modeling
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which all component molecules are uniformly distributed
and they can access to each other with equal probability.
And this assumption reduces the complexity of biochemical
reaction modeling by considering only temporal changes of
molecules rather than their localization.
(b) The law of mass action was used for presentation of all of the
reactions in our model mainly including the binding-
dissociation reactions and the enzymatic reactions. Although
the commonly used reaction model for enzymatic reaction is
the Michaelis-Menten equation which is the famous
simplification of the law of mass action, we only use the
classic law of mass action for all of the enzymatic reactions in
the pathway modeling.
(c) In the pathway, IKKa and IKKb were called the same
name IKK and we did not explore their different functions
no matter what in canonical or noncanonical NFkB
activation pathway.
Figure 2. Qualitative NFkB pathway along with description of considered inhibitors. Firstly, the key cytokine TNFa binds to its receptor,
leading to the recruitment of its adaptors and TRAFs, to form a complex which phosphorylates and activates IKKK, and the phosphorylated IKKK
further activates IKK, leading to the phosphorylation and subsequent degradation of IkBa by 26 s proteasome. The direct consequence is the
translocation of NFkB from the cytoplasm into the nucleus, leading to transcription of target genes. Meanwhile, NFkB also activates its own inhibitor,
IkBa, giving rise to a negative feedback control [28]. By the way, four kinds of specific inhibitors with different targets are also described along with
the qualitative NFkB pathway for the purpose of simulation protocols.
doi:10.1371/journal.pone.0014750.g002
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and IkBe because, under constitutive activity of IKK, NFkB
does not directly induce re-synthesis of these proteins.
Therefore, their presence becomes negligible in the steady
state [14].
(e) We did not consider the reactions of the binding and
dissociation between NFkB and the complex of IkBa and
IKK which were also mentioned in [15].
(f) We did not specify the components about NFkB heterodi-
mer isoforms and we just simply considered the single NFkB
isoform p50/p65 in our model similarly as considered in
other literatures [14,15,16].
Construction of quantitative system for specific NFkB
pathway in MM
From the description of Figure 3, using the law of mass action,
we can build the whole ODEs system for the considered NFkB
model in MM. Generally, there are total 26 components in the
model and 26 ODEs, and the total number of the parameters in
the model is 39. It is worth noting that this ODEs model is
motivated, but different, from various computational models for
NFkB pathway in literatures [14,15,16]. By referring to these
literatures, we collect the parameter values and initial concentra-
tions of the components on the model. As expected that the
simulation results from this ODEs model with these parameters
and initial value sets for cytoplasmic IkB and nuclear NFkB
presented an oscillation phenomenon as shown in Figure S1. The
model consists of a series of ODEs describing the time evolution of
concentrations of various molecules and molecular complexes of
interest. The ODEs model involving four sub-systems are
described in Materials and Methods.
A direct attempt to use the existed model parameters to describe
our experimental data obtained from the human MM.1S cell line
as described in Materials and Methods did not yield satisfactory
result and the result is shown in Figure S2, which was not
unexpected since different experimental models can yield different
model parameters, and also the determination of the model
parameters of signaling pathways is subject to uncertainty and
non-identifiability of kinetic parameters of the enzymes involved in
signaling as mentioned in [17]. We therefore carried out
parameter fitting of the model to the dynamic experimental data
described in Materials and Methods. The whole parameter
estimation procedure in this study is referred to the method
presented in [17] and the optimization procedure is implemented
using DBsolve software with the version 7.48 [18,19]. We use the
following formula for parameter estimation.
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Figure 3. Graphical model for the reactions of NFkB pathway. Based on the different functions of components in the pathway, the whole
system can be divided into four sub-systems. Different sub-systems in the pathway are shown in different colors. Yellow represents the TNFa receptor
sub-system, pink represents the IKK phosphorylation cascade sub-system, green represents the cytoplasmic IKK-IkB-NFkB sub-system, and blue
represents the nuclear IkB-NFkB sub-system, respectively. All of the model parameters are also shown at the side of the corresponding reaction
arrows, and the symbols are chosen based on the different meanings, for example, symbol ‘a’ means association or binding rate, ‘d’ means
dissociation rate, ‘c’ means catalysis rate, and so on.
doi:10.1371/journal.pone.0014750.g003
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respectively. V represents the candidate of parameter space for
optimization procedure, in which the search space for each
parameter is fixed between 0 and 1.
In this procedure, the square error between the experimental
and theoretical data is adopt for the cost function and then the
Hook-Jeevse algorithm [20] is adopt to minimize the cost function
in Equation (1). It is worth noting that all of the parameters for
TNFa receptor and IKK phosphorylation cascade sub-systems
and all of the initial concentration values in the pathway are kept
the same as those in the literatures, and we use this procedure to fit
the parameters to the experimental MM data for cytoplasmic
IKK-IkB-NFkB sub-system and nuclear IkB-NFkB sub-system,
because the reactions in these two sub-systems are specifically
dependent on the type of cell line. Therefore, the total number of
estimated parameters in this study is reduced to 21 from 39. In the
procedure of optimization, the initial values of 21 estimated
parameters are generated randomly between 0 and 1, and the
desired square error is set at 0.01. In order to analyze the
convergence of the optimization algorithm and to obtain the
optimal estimation results, we execute the program for twenty
times with different initial values. All of the results perform good
convergence targeting the desired error, although the speed of
convergence is not so fast with the average convergence time being
about 7 hours. The final estimation results for the parameters are
obtained by using the average of all the runs with the average
square error being 0.0088. The fitting curves on the model can be
seen from Figure 4 which shows the satisfied fitting results for the
cytoplasmic IkB and nuclear NFkB concentration data after
parameters estimation. The summary for all of the parameters is
listed in Table S1, and Table S2 shows the summary for all of the
initial concentrations in the model. Although there exist some
differences on the model parameters between our fitted model and
the model collected from literatures, the fitted model can reflect
the experimental data well. Therefore, we will use this model for
the further analysis in our study.
Parameter sensitivity analysis is a tool to quantitatively
determine the effect that specific parameters on the output. To
understand the relationship between system responses and
variations in individual model parameter values, local parameter
sensitivity analysis was performed. The sensitivity coefficient (S)i s
defined as follows:
SO
P~
LO=O
LP=P
%
DO=O
DP=P
for small DP: ð2Þ
Where O is the system output, i.e. the nuclear NFkB expression,
and P is the set of model parameters involving 39 kinetic
parameters and 11 initial concentrations. Individual parameters
were altered (i.e. increased or decreased) a little bit individually by
1% from their estimated values, and resulting changes in system
output (DO) were determined. The resulting expression essentially
denotes the percentage change in output resulting from 1%
change in parameter Pj. The results of sensitivity analysis on total
39 kinetic parameters and total 11 initial concentrations are shown
in Figure 5. The results show that the model is more sensitive to a
few parameters, i.e. a8, c8, a9, a10, d10, i1, dg3, tr2 and tr3, than
the other parameters, and the results also show that the model is
more sensitive to a few initial concentrations, i.e. IKKK, IKK, the
complex IkB:NFkB, and cytoplasmic NFkB, than the other initial
concentrations, which give us some suggestions on what are the
key kinetic parameters and molecules in the system. Note that the
percentage changes of nuclear NFkB expression in all cases are
less than 0.04%, which shows the constructed pathway model is
very stable, especially for TNFa receptor sub-system and IKK
phosphorylation cascade sub-system corresponding to the param-
eter set from a1 to c7 in Figure 5(A), which shows the rationality
that all of the parameters in these two sub-systems are fixed before
parameter estimation. All of the results for sensitivity analysis are
shown in Figure 5.
Development of a complete system for NFkB pathway in
MM with or without drug treatments
Once we have built the quantitative mathematical model for
NFkB pathway, different drugs with different targets should be
modeled into the constructed ODEs system by specific mecha-
nisms in order to study the different inhibition profiles on single
drugs or drug combinations by simulating the model, meanwhile
these protocols of simulation are also able to predict the optimal
combination on the considered drugs. In this study, we just focus
on the following four kinds of drugs, i.e. Infliximab, Aresenic
tricide (ATO), Bortezomib (BZM) and A238L and we call them
D1, D2, D3 and D4 for the purpose of simplification, and the
corresponding targets are TNFa, IKKp, IkBa degradation and
cytoplasm NFkB, respectively. Figure 2 provides the graphic idea
for these inhibitors in NFkB pathway. The details for the
mechanisms of actions and drug modeling procedure are
presented in Materials and Methods.
Inhibition percentage curves and single-drug evaluations
Once the considered drugs have been modeled into our ODEs
system, we can simulate the whole model by changing the input of
single drug dose, and then to predict the different steady output
values for nuclear NFkB concentration corresponding to the input.
By comparing these values with the control values (i.e. the nuclear
NFkB concentrations in the case without drug input), the
inhibition percentage curves on different single drugs can be
calculated, meanwhile this kind of inhibition curve can be used as
reference to assess the single drug effect. In detail, given the input
of the specific single drug with dose x, the corresponding
inhibition percentage or inhibition rate Ix ðÞ is defined as follows,
Ix ðÞ ~
Onormal{Odrug x ðÞ
Onormal
, ð3Þ
where Onormal is the system output in the normal case, i.e. the
nuclear NFkB expression in the case without drug input, which is
fixed at 0.055 mM in this study according to the previously
estimated model; Odrug x ðÞis the system output in the case with
drug input, which can be obtained from the simulation of model.
It is shown from the simulation of single drug D1 with the
normal binding rate that the inhibition effect is negligible
regardless of the huge and unreasonable dose 1000 mM, as it
can be seen from the bottom curve in Figure 6(A). It can be
guessed spontaneously that this result may be due to the low rate of
drug binding, so we magnify the binding rate by 5, 10 and 100
times higher than the normal one, then run the simulation again.
The results in Figure 6(A) show that the inhibition effects are still
very low and just about 2%, 4%, 8% and 34% corresponding to
Drug Prediction from Modeling
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of the binding rate is not significant to explain the ineffectiveness of
D1. By another simulation, we try to seek the relationship between
the nuclear NFkB concentration and the initial concentration of
ligand TNFa. The predicted result shows that about 0.0003 mM,
0.001 mM and 0.0048 mM TNFa, i.e. about 0.15%, 0.5% and
2.4% of normal initial TNFa dose 0.2 mM, can sufficiently lead to
50%, 70% and 90% nuclear NFkB output comparing to the
normal case, as it can be seen in Figure 6(B). This result suggests
that the stimulus of TNFa with 0.2 mM concentration is largely
redundant to stimulate the production of the nuclear NFkB, which
is consistency with the clinical result of high expression of TNFa in
MM. Therefore, we claim that D1 is nearly no effect to inhibit the
NFkB pathway in MM due to the large redundancy of TNFa
expression.
It is shown from the inhibition profiles in Figure 7 that there
exist different types of profiles for D2, D3 and D4. It can be
concluded that D2 and D4 share the similar inhibition profile with
hyperbolic type function, but D3 has the different inhibition
profile with sigmoidal type function. Note that there exist some
extremely different properties between these two types of
functions, as pointed out in Figure 7 that tripling dose just
increases the inhibition effect 20% and 30% for D2 and D4, but
increases 15 fold of the effect for D3. From this character, to
certain extent we can conclude that D3 is much better than D2
and D4 if we want to choose a single drug to inhibit the NFkB
pathway. Of course, we omit some other factors, such as side-
effect, economical consideration, and so on. It is worth noting that
this drastic difference between these two types of inhibition profiles
underscores the difficulty to predict by inspection what would be
the ‘‘additive effect’’ when two drugs are combined at a given
ratio. By the way, from this kind of profile, we can easily get the
predicted IC values for different inhibition percentages, like IC25,
IC50 and IC75, for example, IC50 represents the concentration of a
Figure 4. Data fitting results. This is the data fitting results for cytoplasmic IkB (A) and nuclear NFkB (B). Black box and solid curve represent the
experimental data point and simulated results from the model after parameter estimation, respectively. In the coordinate system, X and Y axes
present time and concentration, respectively.
doi:10.1371/journal.pone.0014750.g004
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used in the drug combination study.
Combination index and drug combination evaluations
It is well-known that, for drug combination, two drugs working
together maybe can produce an effect greater than the expected
combined effect of the same agents used separately, and we call
this case as synergy combination. Otherwise, we call the
combination as additive effect (i.e. equivalent effect) or antagonism
(i.e. less effect). In addition, different ratio combinations of dose for
the same two drugs sometimes can produce totally different effects,
such as one combination is synergistic but another is antagonistic.
Therefore, it is also significant to predict the synergy combinations
of dose ratios using computational model. Although a number of
available mathematical combination indexes can be used to assess
the effect of drug combination, in this study we prefer to select
Bliss independence [21], because it is not only a famous synergy
quantification method but also extremely convenient for calcula-
tion. Firstly, we briefly introduce the Bliss independence idea as
follows. Let f1, f2 and f12 denote the effects for single drug 1,
single drug 2 and the drugs 1&2 combination respectively, then it
is firstly defined the combination as Bliss synergy if
f12wf1zf2{f1   f2, Bliss additive if f12~f1zf2{f1   f2,
and Bliss antagonism if f12vf1zf2{f1   f2. In this study,
following the Bliss independence idea mentioned above, we then
define a Bliss combination index as follows, CIBliss~
f1zf2{f1   f2 ðÞ =f12. Given threshold_up and threshold_
down, the effect of drug combination is defined as synergy if
CIBliss , threshold_down, and antagonism if CIBliss . thresh-
old_up, otherwise additive. In this study, the thresholds are fixed
as threshold_down=0.99 and threshold_up=1.01, i.e. 1%
perturbation by noise is tolerated. In the simulation procedure,
the Bliss combination index will be used to assess the synergy of
drug combinations. In this study, the inhibition rate I defined in
Equation (3) will be applied as the index of the drug effect. So, we
give the definition of the Bliss combination index in details here.
For drug 1 and drug 2, given the system input with dose
combination x,y ðÞ , the corresponding Bliss combination index
CIBliss(x,y) is defined as follows,
CIBliss x,y ðÞ ~
I1 x ðÞ zI2 y ðÞ {I1 x ðÞ I2 y ðÞ
I12 x,y ðÞ
, ð4Þ
where I1 x ðÞ and I2 y ðÞ are the inhibition rates for the single drug 1
with dose x and the single drug 2 with dose y, respectively, which
are defined in Equation (3); I12 x,y ðÞ is the inhibition rate for the
drug 1 & drug 2 combination with dose x,y ðÞ , which has similar
definition as mentioned in Equation (3).
Based on the prediction of inhibition profiles for D2, D3 and D4
shown in Figure 7, we choose suitable ranges of dose for each drug
Figure 5. Parameter sensitivity analysis of the model. The above subfigure (A) shows the result of model sensitivity on total 39 kinetic
parameters, and the below subfigure (B) shows the result of model sensitivity on 11 initial concentrations of corresponding molecules in the model.
The results show the stability of the constructed pathway model and also give some suggestions on what are key kinetic parameters and molecules
in the model.
doi:10.1371/journal.pone.0014750.g005
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0,0.02 mM for D3 and 0,1 mM for D4. It is worth noting that
the chosen dose ranges are consistent with biological consideration
at least for D2 (ATO) and D3 (BZM). We evenly divide each range
into 100 equal portions and then calculate the corresponding Bliss
combination index defined previously for each combination. Note
that the total number of dose combinations for each two-drug
combination is equal to 10,000. The simulation results for heat-
maps of Bliss combination index are shown in Figure 8. Note that
the threshold parameters, i.e. threshold_up and threshold_down
previously defined in the Bliss evaluation are fixed at 1.01 and 0.99
respectively, of course, other perturbations with more or less
intensity are also considered for testing and the similar results also
can be obtained. It can be found from Figure 8 that all of three
Figure 6. Nearly no effect for D1. (A) Several inhibition profiles of D1 on nuclear NFkB corresponding to different binding rates; (B) Normalized
nuclear NFkB concentration curve on the initial concentration of TNFa. We change the drug dose in a huge range from 0 uM up to 1000 uM to look
over the inhibition percentage. The red inhibition curve is based on the normal drug binding rate. It shows, throughout the dose range, the inhibition
percentage is less than 3%, almost no effect. Then we magnify the binding rate by 5, 10 and 100 times, but the inhibition results are still not
significant. So we claim it is nearly no effect for D1, it means that it is not a good idea using D1 to inhibit the NFkB pathway. Note that this result is
consistent with the clinical result of very high expression of TNFa in MM.
doi:10.1371/journal.pone.0014750.g006
Drug Prediction from Modeling
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different inhibition profiles corresponding to different dose
combinations. For D2&D3, most of the dose combinations are
detected as antagonistic effect because most regions display in red
color in the corresponding heat map in Figure 8, and other small
parts of combinations are detected as additive effect, and this result
is also applicable if we just focus on the region within IC50 values.
For D2&D4, synergistic effect is detected for most dose
combinations fortunately, meanwhile no antagonistic effect has
been detected and all the remains are additive. Moreover, almost
all of the dose combinations within IC50 region are shown as
synergistic. For D3&D4, all of three types of combination effects
have been detected, but just additive and antagonistic effects are
shown within IC50 region. From these combination profiles, it can
be concluded that the D2&D4 drug combination is the best
choice, D2&D3 is the worst one and D3&D4 is the mediacy,
meanwhile the predicted synergistic regions in D2&D4 and
D3&D4 combinations are potentially helpful to conduct the
clinical drug combination experiment.
Discussion
As we mentioned in the previous text, inhibition of NFkB
activation has been proposed as a potential therapeutic strategy in
the treatment of MM. Although different drugs, such as the drugs
considered in this work, with different targets can be used to
inhibit the NFkB pathway, no detailed drug-effect profiles have
been reported in literatures. So, the aim of this work is to
comparably assess the inhibition profiles for specific single drugs
and drug combinations, especially for the prediction of synergy on
drug combinations. We used the computational pathway modeling
combining with dynamic experiment data to do this work. At first,
the dynamic experimental data are used to build the computa-
tional pathway system. Then the simulation protocols are figured
Figure 7. Different types of inhibition profiles on single drugs D2, D3 and D4. Different inhibition profiles on nuclear NFkB production by
different single drugs D2 (A), D4 (B) and D3 (C). The above figures show two types of functions on the inhibition profiles, that is, hyperbolic type
function for both D2 and D4, but sigmoidal type function for D3. It also shows that there exist extremely different characters between these two
types of functions. For example, triple the D2 dose from 1 uM to 3 uM, the inhibition effect only increase 20%. Triple the D4 dose, it also only increase
30%. But, triple the D3 dose, it can produce 15 fold increase. By the way, from this profile, we can easily get the IC value prediction for different
inhibition percentages, like IC25, IC50, and IC75. For example, IC50 represents the concentration of a drug that is required for 50% inhibition. These
IC values will be used for the drug combination study.
doi:10.1371/journal.pone.0014750.g007
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we put single drug with adjustable dose one by one into the system,
check the output, then compare it with the control case to get the
profile. For the study of drug combination profile or synergy study,
we put two drugs together with adjustable dose combination into
the system, check the output, and then compare it with the control
case to get the profile based on Bliss independence evaluation
quantification method. Finally, the simulation results for the study
of single drugs show that it is nearly no effect for D1 to inhibit the
NFkB pathway, and it also show that there exist different types of
functions for the inhibition profiles of single drugs D2, D3 and D4.
The simulation results for drug combination study show that there
exists strong synergy effect for D2&D4 combination, however
strong antagonism effect has been predicted for D2&D3
combination. Note that the result for D2&D3 combination is
consistent with our previous study in [22,23] which suggested that
although the synergy occurred on proliferation inhibition of
human MM cells for D2&D3 drug combination treatment, this
synergy effect was mainly reflected in JNK pathway rather than
NFkB pathway. It is also worth noting that the D2&D4
combination has the potential to work in synergism by our model
simulation although this predicted result has not been reported,
and the validation by further biological experiment in our
laboratory should take long time due to the procedure of cell
Figure 8. Synergy prediction on D2&D4 combination based on Bliss combination index. Heat maps of different drug combinations, i.e.
D2&D3, D2&D4 and D3&D4, based on Bliss combination index to predict the synergistic region for combination. Different types of combination
effects are shown in different color in the heat maps, and the description of definitions for Bliss combination index and three types of combination
effects are also shown in the bottom-left.
doi:10.1371/journal.pone.0014750.g008
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experiment in biology.
In order to test the consistency of the predicted results for drug
combinations, another synergy quantification method has also
been employed for this purpose. As we know, the two most used
reference models for quantifying synergy are Bliss independence
[21] and Loewe additivity [24]. And, the Loewe additivity model,
along with the associated graphical concept of the isobologram, is
usually used by combining with Bliss independence to explore
more information for the prediction of drug combinations. Herein,
we briefly introduce the concept of Loewe synergy. The general
visualized description of Loewe synergy can be seen from Figure
S5, in which the combination index of Loewe synergy for drug 1 &
drug 2 is defined as CI~d1
.
IC
1 ðÞ
x zd2
.
IC
2 ðÞ
x , where d1,d2 ðÞ is the
drug combination dose located in the combination contour line or
isobologram, IC
i ðÞ
x (i=1, 2) denotes the x% percentage-based
inhibition concentration of drug i and IC50 is the classic one as we
mentioned previously. As mentioned in the sub-figure box of
Figure S5, CIv1,~1 andw1 indicate Loewe synergism, additive
effect, and antagonism, respectively. As it can be shown from
Figure S5, as an example of Loewe synergy, that the red solid
contour line is a 50% isobologram, i.e. the locus of d1,d2 ðÞ
combination points producing the 50% inhibition, and we say that
it has Loewe synergy for all the combination of drug 1 & drug 2 at
all the combination ratios since the contour bows inward.
From the simulation of mathematical model, we calculate the
Loewe isobolograms for different drug combinations based on
different inhibition percentages. The results are presented in the
Figure S6 for drug combinations D2&D3, D2&D4 and D3&D4 at
inhibition concentrations IC25, IC50 and IC75. Using the concept
of Loewe synergy, we can obtain some results from the Figure S6
that for drug combination D2&D3, only strong antagonism is
presented because all the isobolograms IC25, IC50 and IC75 are
outward strongly; for drug combination D2&D4, the weak
antagonism is presented at IC25 and IC50, fortunately the strong
synergism is presented in the case of IC75 because the 75%
isobologram is inward strongly; for drug combination D3&D4, the
strong antagonism is presented at IC25 and IC50, however all of
three kinds of drug combination effects, i.e. synergism, additive
effect and antagonism, are presented in the case of IC75, which
means that it is able to produce different effects corresponding to
different dose combinations. We conclude from the Loewe synergy
analysis that both of the drug combinations D2&D4 and D3&D4
can produce synergy effect, but not for the combination D2&D3.
This kind of result is consistent with that from Bliss independence
quantification method, which may be potentially useful for the
selection of drug combinations in the chemical therapy.
There exist two limitations in this current work. One is that only
one key pathway (in this case, NFkB pathway induced by TNFa
treatment) is considered here, and another is that the molecular
output in the pathway (in this case, nuclear NFkB expression) is
not linked to specific cell phenotypic behaviors in MM. At first, a
pathway-centric approach remains incomplete because of the
intricate cross talks among cell regulatory pathways [25]. Indeed, a
given molecular component can be identified to be associated with
or interact with multiple signaling. Pathways thus cannot properly
be considered to operate in isolation of one another, as an
alteration of one pathway can lead directly or indirectly to changes
in others. To address this problem, a specific growing approach
has been proposed in our laboratory used to expand the seed
pathway (in this case, NFkB pathway) by combining protein-
protein-interactions (PPI) information with Microarray data of
MM cell line. In brief, given the set of interested genes and
proteins as the seeds, we can construct the generic pathway map
by growing those seeds based on the interaction database. Further,
we will integrate the experimental data to determine the signaling
process and positive/negative feedback loops in the expanded
network. Finally, the single NFkB pathway can be expanded to
multi-pathways in order to solve this problem. For the second
limitation, most of the current work-like system modeling efforts
aimed at predicting the effects of therapeutic perturbations of cell
regulatory pathways, i.e. restricted its attention to predict
molecular-level processes (in this case, nuclear NFkB expression).
What is vital, of course, is to predict the effects of these
perturbations on cell phenotypic functions at the very least. The
most difficult problem is to connect the molecular-level pathway
activities to the cell-level functional behaviors, even in absence of
therapeutic perturbations. Fortunately, relational modeling meth-
ods, such as partial least squares regression [26] and quasi-non-
parametric/generalized model [27], which both link the key
phosphorylated proteins to the cell fate decisions using specific
linear/non-linear functions, can be employed as the most effective
approaches to solve this problem.
Materials and Methods
Dynamic experimental data
Although there were a few computational models for the NFkB
pathway and most of the model parameters have been identified
[14,15,16], all of these models did not focus on the specific MM
cell line. In this study, we focus on the specific NFkB pathway in
MM. So it is necessary to validate and rectify the model obtained
from the literatures based on the experimental data produced from
the specific human MM cell line. For this purpose, we have
collected different types of data from literatures [11,12] and also
from our laboratory. We firstly point out that all of these data are
produced from human MM.1S cell line stimulated with 0.2 uM
TNFa, which is consistent with our model in this study because
our model is also focused on MM with 0.2 uM TNFa stimulation.
Herein we obtained some time-course experimental data on
protein expression for key components of NFkB pathway in MM,
including the cytoplasmic IkB data with 6 time-points at 0, 5, 10,
15, 20, and 30 minutes from western blot experiment in [11,12],
and the nuclear NFkB data with 6 time-points at 0, 10, 20, 30, 60,
and 120 minutes from electrophoretic mobility shift assay (EMSA)
in [11,12] and flow cytometry experiment in our laboratory, which
are shown in Figure S3. These dynamic time-course data are
obtained by calculating the mean of all the corresponding data at
each time-point. It is worth noting that the same time-points for
the cytoplasmic IkB data and the nuclear NFkB data is not
essential in the procedure of parameter estimation because the
proposed optimization algorithm is able to handle this kind of data
by minimizing the sum of square errors between the experimental
data and the simulation data for all of the considered time points,
as described in the section of parameter estimation in the previous
text.
ODEs system of NFkB pathway in MM
Here we describe the details for the ODEs system, but just list
the equations for TNFa receptor sub-system as an example and
the details for other three sub-systems are provided in Text S1 of
Suppoting Information.
Module 1- TNFa receptor sub-system
This module describes the process from the binding of TNFa
with its receptor to the formation of complex after recruitment.
TNFa: Equation (5) describes the changes on the concentration
of TNFa due to binding (with rate a1) to its receptor TNFR1 and
dissociation (with rate d1) from the complex TNFa:TNFR1
Drug Prediction from Modeling
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d TNFa ½ 
dt
~{a1   TNFa ½  TNFR1 ½  zd1   TNFR1C ½  ; ð5Þ
TNFR1: Equation (6) describes the changes on the concentration
of TNFR1 due to binding (with rate a1) to its ligand TNFa and
dissociation (with rate d1) from the complex TNFR1C.
d TNFR1 ½ 
dt
~{a1   TNFa ½  TNFR1 ½  zd1   TNFR1C ½  ; ð6Þ
TNFR1C: Equation (7) describes the changes on the concentra-
tion of the complex TNFR1C due to association & dissociation
mechanism between two teams of proteins, in which one is
between TNFa and TNFR1 (with rates a1 and d1) and another is
between TNFR1C and TNFR1 adaptor (TNFR1A) (with rates a2
and d2).
d TNFR1C ½ 
dt
~a1   TNFa ½  TNFR1 ½  {d1   TNFR1C ½  {
a2   TNFR1C ½  TNFR1A ½  zd2   TNFR1AC ½  ;
ð7Þ
TNFR1A: Equation (8) describes the changes on the concentration
of TNFR1A due to binding (with rate a2) to the complex
TNFR1C and dissociation (with rate d2) from the complex
TNFR1:TNFR1A (TNFR1AC).
d TNFR1A ½ 
dt
~
{a2   TNFR1C ½  TNFR1A ½  zd2   TNFR1AC ½  ;
ð8Þ
TNFR1AC: Equation (9) describes the changes on the concentra-
tion of the complex TNFR1AC due to association & dissociation
mechanism between two teams of proteins, in which one is
between TNFR1C and TNFR1A (with rates a2 and d2) and
another is between TNFR1AC and TRAFs (with rates a3 and d3).
TRAFsC represents the complex TNFR1AC:TRAFs.
d TNFR1AC ½ 
dt
~
a2   TNFR1C ½  TNFR1A ½  {d2   TNFR1AC ½  {
a3   TNFR1AC ½  TRAFs ½  zd3   TRAFsC ½  ;
ð9Þ
TRAFs: Equation (10) describes the changes on the concentration
of TRAFs due to binding (with rate a3) to the complex TNFR1AC
and dissociation (with rate d3) from the complex TRAFsC.
d TRAFs ½ 
dt
~
{a3   TNFR1AC ½  TRAFs ½  zd3   TRAFsC ½  ;
ð10Þ
TRAFsC: Equation (11) describes the changes on the concentra-
tion of the complex TRAFsC due to association & dissociation
mechanism between two teams of proteins, in which one is
between TNFR1AC and TRAFs (with rates a3 and d3) and
another is between TRAFsC and IKKK (with rates a4 and d4). In
addition, TRAFsC is also retrieved (with rate c4) after catalysis
from the complex TRAFsC:IKKK.
d TRAFsC ½ 
dt
~
a3   TNFR1AC ½  TRAFs ½  {d3   TRAFsC ½  {
a4   TRAFsC ½  IKKK ½  z d4zc4 ðÞ   TRAFsC : IKKK ½  ;
ð11Þ
Mechanisms of actions and drug modeling
Firstly, we introduce the mechanisms of actions for the
considered drugs. In general, D1, D2 and D4 share the similar
mechanism to inhibit the corresponding targets by binding
mechanism. However, D3, with different mechanism, works to
inhibit the degradation of IkBa by blocking the activity of
proteasome. Based on these mechanisms, we got the drug
modeling description as follows.
For D1, we assume it competitively inhibits TNFa with the
same binding kinetics as that of the reaction involving TNFa and
its receptor, that is, the binding rate is set as a1 and the dissociation
rate is set as d1. So, we add a new equation for D1 into the system,
meanwhile we also modify an old equation for TNFa. For D2 and
D4, it is similar with D1. The details of mechanism of actions and
drug modeling for D1, D2 and D4 are provided in Text S2 of
Supporting Information.
For D3 (i.e. BZM), it is the first therapeutic proteasome inhibitor
to be tested in human and it has been approved in the US for
treating relapsed MM. D3 works to inhibit the degradation of IkBa
byblockingtheactivityofthe proteasome.Forsimulating this drug’s
effect, we could not directly introduce an additional component to
the system similarly as D1 because the degradation process of IkBa
is not explicitly established in the ODEs model. By referring to [14],
we can adjust the corresponding parameters in the terms for NFkB
released after the degradation of IkBa, and the individual terms for
IkBa and NFkB:IkBa molecules rescued from degradation. In
order to describe the dose effect of D3 on the terms mentioned
above, we introduce a Hill-type function to describe the inhibition
rate for IkBa degradation by D3, which is defined as follows,
r~ D3 ðÞ
k0
.
K0z D3 ðÞ
k0
hi
ð12Þ
Where D3 denotes the concentration of drug D3 and k0 is set by 4
and K0 by 10e-10, and the corresponding curve can be seen from
Figure S4 in which the corresponding concentration resulted in
50% inhibitionis about 0.0055 mM. Referred to Figure 3, all of four
terms related to the action of D3 are modified as follows,
d10~d’ 10zr   c’ 10, c10~ 1{r ðÞ   c’ 10, d8~d’ 8zr   c’ 8 and c8~
1{r ðÞ   c’ 8, where d’ 10, c’ 10, d’ 8 and c’ 8 represent the parameters
before modification, and d10, c10, d8 and c8 represent the
parameters after modification.
Supporting Information
Figure S1 Oscillation phenomenon. Oscillation phenomenon is
presented in the model that constructed from literatures for
cytoplasmic IKKp (A), cytoplasmic IkB (B) and nuclear NFkB (C).
In the coordinate system, X and Y axes present time and
concentration, respectively.
Found at: doi:10.1371/journal.pone.0014750.s001 (0.27 MB TIF)
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can not fit the experimental data. Data fitting results for
cytoplasmic IkB (A) and nuclear NFkB (B). Black box and solid
curve represent the experimental data point and simulated results
from the model with the collected parameters from literatures,
respectively. In the coordinate system, X and Y axes present time
and concentration, respectively.
Found at: doi:10.1371/journal.pone.0014750.s002 (0.66 MB TIF)
Figure S3 Dynamic experimental data. The left sub-figure
shows the western blot data for cytoplasmic IkB including five
samples with up to six time-points, and the right sub-figure shows
the EMSA data including two samples with three time-points and
flow cytometry data with six time-points for nuclear NFkB. The
above sub-figure shows the original experimental data and the
corresponding quantified data based on the mean value is shown
in the below sub-figure.
Found at: doi:10.1371/journal.pone.0014750.s003 (0.52 MB TIF)
Figure S4 Inhibition rate curve for IkBa degradation by BZM.
Based on the definition in Equation (12) of the main text under the
assumption of Hill-type function, the presented curve can be used
to describe the dose effect of BZM on the degradation of IkBa,i n
which the unit of BZM concentration in the X axes is mM. Note
that the corresponding concentration resulted in 50% inhibition is
about 0.0055 mM as pointed out in the curve.
Found at: doi:10.1371/journal.pone.0014750.s004 (0.22 MB TIF)
Figure S5 Loewe synergy description based on classic IC50 -
isobologram. According to the definition of the combination index
in the right box, the drug combinations for point A, B and C
indicate Loewe synergism, additive effect and antagonism,
respectively; since the 50% isobologram from the left sub-figure
is the red solid curve rather than the black dash-line or green dash-
curve, it means that all of the combinations present Loewe synergy
for drug 1 & drug 2.
Found at: doi:10.1371/journal.pone.0014750.s005 (0.38 MB TIF)
Figure S6 Loewe isobolograms for different drug combinations
in different cases of IC values. The blue contours in each sub-
figure indicate the corresponding isobolograms, in which the
column is for drug combination and the row is for inhibition
percentage. For D2&D4 combination, in the case of IC75, a
strong synergy effect can be found, however strong antagonism
always can be seen in all of the cases of different IC values for
D2&D3 combination. Note that this result is consistent with the
result based on Bliss independence.
Found at: doi:10.1371/journal.pone.0014750.s006 (0.39 MB TIF)
Table S1 Summary of the total 39 kinetic parameters in model.
Found at: doi:10.1371/journal.pone.0014750.s007 (0.14 MB
DOC)
Table S2 Summary of the initial concentrations in the model.
Found at: doi:10.1371/journal.pone.0014750.s008 (0.07 MB
DOC)
Text S1 The details of ODEs system for other three sub-systems
in the model except for TNFI ˆ6 receptor sub-system.
Found at: doi:10.1371/journal.pone.0014750.s009 (0.30 MB
DOC)
Text S2 The details of the mechanism of actions and the drug
modeling for other three drugs in the model except for D3.
Found at: doi:10.1371/journal.pone.0014750.s010 (0.08 MB
DOC)
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